Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01945593 · ClinicalTrials.gov registry record · Phase 3
BAX 855 Continuation
A Phase 3 study, sponsored by Baxalta now part of Shire.
- Completed
- Registry status
- Phase 3
- Development phase
- 218
- Enrollment target
NCT01945593 is a Phase 3 study that has completed, run by Baxalta now part of Shire. The registered enrollment target is 218 participants.
The verdict
NCT01945593, a Phase 3 study, has completed, sponsored by Baxalta now part of Shire.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 218 participants
- Enrollment target
Study Summary
To continue the evaluation of the safety and efficacy of BAX 855 for prophylaxis and treatment of bleeding episodes in adult and pediatric previously treated patients (PTPs) aged ≤ 75 years of age with severe hemophilia A.
Interventions
- BIOLOGICAL BAX855
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 218 participants |
| Start Date | 2013-10-15 |
| Est. Completion | 2018-03-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01945593
The ClinicalTrials.gov registry entry for NCT01945593 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 218 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baxalta now part of Shire, which has 74 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which BAX855 is the first listed.
NCT01945593 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01945593 about?
NCT01945593 is a clinical study titled "BAX 855 Continuation". To continue the evaluation of the safety and efficacy of BAX 855 for prophylaxis and treatment of bleeding episodes in adult and pediatric previously treated patients (PTPs) aged ≤ 75 years of age with severe hemophilia A.
What is the current status of trial NCT01945593?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 218 participants. The study started on 2013-10-15. Estimated completion is 2018-03-02.
What interventions are being tested in trial NCT01945593?
The interventions under investigation include: BAX855 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01945593?
This trial is sponsored by Baxalta now part of Shire, which has 74 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.